HOME >> BIOLOGY >> NEWS
International study findings link acne-like rash to effectiveness of new targeted cancer treatment

Geneva, Switzerland: Acne is not a condition that anyone would welcome under normal circumstances, but an international study of a new targeted cancer treatment cetuximab has shown that patients who developed an acne-like rash responded better to the treatment than those who did not.

Professor Eric Van Cutsem told a news briefing today (Thursday 30 September) at the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics that a trial, conducted in Belgium and the USA, had demonstrated that the more severe the rash the better the patients' tumours had responded to the treatment and the longer was their median survival.

Professor Van Cutsem, who is head of the Digestive Oncology Unit and Professor of Medicine at University Hospital Gasthuisberg in Leuven, said 346 patients with advanced colorectal cancer were treated in the study in Leuven and other Belgian and U.S. centres.

All the patients had metastatic cancer and had failed to respond to at least two prior chemotherapy regimens, although all still had a reasonable quality of life, either being fully active or at least still able to carry out light work.

Cetuximab, also known as Erbitux, is a new targeted treatment a monoclonal antibody designed to home in selectively on a protein called the epidermal growth factor (EGFR). EGFR is found on the surface of some cells and plays a role in regulating cell growth. Cetuximab interferes with the growth of cancer cells by binding to EGFR. It is approved by the Food and Drug Administration in the USA for use with the cancer drug irinotecan for colorectal cancer that has failed other treatments. It is also the first monoclonal antibody targeting EGFR to have gained marketing authorisation in Europe and is now being evaluated in first-line treatment of colorectal cancer, with promising results.

Professor Van Cutsem said that the acne-like rash was also a side effect of other EGFR inhibitors but it was not
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
30-Sep-2004


Page: 1 2

Related biology news :

1. USAID, Conservation International & Starbucks launch Conservation Coffee Alliance in Central America
2. ConocoPhillips & Conservation International launch Biodiversity Action Plan in Venezuela
3. A room with a view for the International Space Station: Completion of the cupola observation module
4. International symposium on nutritional genomics
5. First International Scientific Conference on Childhood Leukaemia
6. 1st International Conference on Cell Therapy for Cardiovascular Disease
7. International research conferences at the Villa Vigoni
8. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
9. STN International launches Derwent World Patents Index First View
10. Media invited to attend International Society For Heart & Lung Transplantation meeting April 21-24
11. International critical care doctors release first-ever guidelines for sepsis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2020)... ... 13, 2020 , ... Acumed LLC today announced that it ... of the Louisville-based company’s orthobiologics portfolio. Under the terms of the agreement, Acumed ... phosphate-based bone allograft (Trabexus) and calcium phosphate-based biocement (Fortera). Vivorte will continue to ...
(Date:3/11/2020)... ... 11, 2020 , ... Polysense Technologies Inc., (Polysense) an innovation ... infrared touch-free monitoring product family, a standalone thermal meter WxS x800-IRTMS, and an ... for cloud connectivity such as NB-IoT, Wi-Fi, LoRaWAN, and 4G LTE, , “Temperature ...
(Date:3/9/2020)... ... March 09, 2020 , ... ... a steep growth rate of 64% last year, as enterprises sought to ... from Everest Group. Unfortunately, only 13% of all transformation efforts delivered the ...
Breaking Biology News(10 mins):
(Date:3/19/2020)... ... March 17, 2020 , ... ... and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. ... ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s ...
(Date:3/13/2020)... ... 2020 , ... Today, DuPont Nutrition & Biosciences (DuPont) announced ... pioneer in the field of microbiome science, which focuses on microbes that live ... based at University College Cork and Teagasc Moorepark. , Representatives from both organizations ...
(Date:3/10/2020)... (PRWEB) , ... March 10, 2020 , ... Ortho Clinical ... through innovative laboratory solutions, announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen ... transfusion, is cleared to run on ORTHO VISION® and ORTHO VISION® Max in the ...
(Date:3/10/2020)... (PRWEB) , ... March 10, 2020 , ... Lifecycle ... on 13 acres in Cleburne, Texas to be used as a biopharmaceutical and biotechnology ... global headquarters and sales offices as well as its production and development hub. The ...
Breaking Biology Technology:
Cached News: